BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2020
Bergen, Norway, 10 February 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the fourth quarter and full year 2020. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CET today, please see below for details. Operational Highlights – fourth quarter (including post-period end) · First patient enrolled in South Africa and India as part of Company sponsored randomised Phase II trial assessing bemcentinib as a